Healthcare / BiotechnologyShenzhen
$10.00
+0.03 (+0.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
90.9x
↑EV/EBITDA
59.4x
↑ROE
3.0%
↑Gross Margin
27.1%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+27.0%
FCF CAGR
—
FCF margin
7.9%
FCF / Net income
2.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $868.6M · net income $30.5M · FCF $68.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $868.6M | $868.6M | $742.0M | $555.8M | $423.7M |
| Net Income | $30.5M | $30.5M | $28.8M | $24.3M | $27.7M |
| EBITDA | $59.9M | $59.9M | $48.8M | $42.4M | $46.8M |
| EPS | 0.08 | 0.08 | 0.08 | 0.07 | 0.08 |
| Gross Margin | 27.1% | 27.1% | 30.4% | 33.3% | 37.9% |
| Operating Margin | 6.9% | 6.9% | 5.5% | 5.9% | 8.2% |
| Net Margin | 3.5% | 3.5% | 3.9% | 4.4% | 6.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.12 | 0.09 |
| Current Ratio | 1.92 | 1.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $68.3M | $68.3M | $-2.6M | $-26.2M | $-89.6M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 3.0% | 2.5% | 3.2% |
| Valuation | |||||
| P/E | 90.91 | 90.91 | 109.04 | 135.06 | 104.52 |
| EV/EBITDA | 59.43 | 59.43 | 59.67 | 70.76 | 56.99 |
| P/B | 3.75 | 3.75 | 3.22 | 3.44 | 3.38 |
| Growth & Yield | |||||
| Revenue Growth | 17.1% | 17.1% | 33.5% | 31.2% | — |
| EPS Growth | 5.6% | 5.6% | 14.6% | -12.9% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
123.6%
EPS terminal req.
$0.89
Spread vs growth
-118.0%
5Y implied EPS CAGR
68.3%
EPS terminal req.
$1.07
Spread vs growth
-62.8%
10Y implied EPS CAGR
36.1%
EPS terminal req.
$1.73
Spread vs growth
-30.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.8%
Start / end P/E
109.3x → 125.9x
EPS bridge
0.08 → 0.08
Residual
+0.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.